Canine leukoreduction review finds promise, but limited proof

A new critically appraised topic in Veterinary Sciences takes on a practical question in small-animal transfusion medicine: should canine blood products be leukoreduced before storage? The review concludes that prestorage leukoreduction has plausible biologic advantages and measurable effects on blood-product quality, but the clinical payoff in dogs is still not firmly demonstrated. In other words, the science supports interest, not certainty. (pmc.ncbi.nlm.nih.gov)

That conclusion fits the broader trajectory of veterinary transfusion medicine. Leukoreduction is routine in much of human medicine, where it is used to reduce leukocyte-associated complications, but adoption in veterinary practice has been uneven because of cost, workflow demands, and a thinner evidence base. The AVHTM’s 2021 Transfusion Reaction Small Animal Consensus Statement said there was insufficient evidence to recommend for or against leukoreduction for preventing transfusion reactions in dogs and cats, underscoring how unresolved the issue has remained even as blood banking in companion animals has become more sophisticated. (onlinelibrary.wiley.com)

The underlying rationale is straightforward. Leukocytes in stored blood remain metabolically active and can contribute to cytokine accumulation, oxidative stress, and other storage lesions. Experimental and in vitro canine studies have shown that prestorage leukoreduction can effectively remove leukocytes while preserving red cell viability, reduce vascular endothelial growth factor release, blunt accumulation of some inflammatory cytokines, and improve selected storage markers. More recent work has also suggested lower malondialdehyde accumulation in leukoreduced packed red blood cells, pointing to a possible reduction in oxidative stress during storage. (pubmed.ncbi.nlm.nih.gov)

Where the evidence gets harder to interpret is at the bedside. A randomized double-blinded clinical trial in 194 dogs found no significant difference between leukoreduced and non-leukoreduced packed red blood cells in transfusion reaction rates, 12-hour packed cell volume change, or survival to discharge. Retrospective studies have also produced mixed results, and a randomized blinded controlled trial in critically ill dogs did not show a clear reduction in post-transfusion inflammatory markers with leukoreduced products. Taken together, the available literature suggests that biologic effects do not yet translate into a consistent, proven clinical benefit for the average canine transfusion recipient. (pubmed.ncbi.nlm.nih.gov)

Industry and expert commentary has been similarly measured rather than enthusiastic. The Merck Veterinary Manual notes that leukoreduced blood products have been associated with decreased rates of febrile nonhemolytic transfusion reactions in dogs, but that statement sits alongside a literature base that remains small and methodologically variable. Educational materials from ACVIM and consensus guidance from AVHTM both frame transfusion medicine as an area where practice is still evolving, especially around controversial issues like product age, compatibility, and reaction prevention. That’s important context for practices weighing whether leukoreduction should be routine, selective, or not yet worth the added cost. (merckvetmanual.com)

Why it matters: For veterinary professionals, this article reinforces a familiar but important message: better-looking blood bags are not the same thing as better patient outcomes. If a hospital or blood bank is considering leukoreduction, the strongest current argument is product-quality optimization and theoretical reduction in inflammatory burden, not definitive proof of improved survival or uniformly lower reaction rates. That distinction matters for inventory planning, client communication, and pricing, especially when pet parents are already facing the cost and urgency of emergency transfusion care. (pmc.ncbi.nlm.nih.gov)

It may also push the field toward a more targeted approach. Rather than asking whether every canine blood product should be leukoreduced, the more useful clinical question may be whether certain patients, such as those with immune-mediated disease, sepsis, repeat transfusion exposure, or heightened risk of inflammatory complications, benefit more than others. Current evidence does not answer that well yet, but it points to the need for larger, better-powered prospective studies with patient-centered endpoints, not just laboratory markers. (pubmed.ncbi.nlm.nih.gov)

What to watch: The next step for this literature will likely be prospective multicenter work that ties leukoreduction to hard outcomes, including reaction rates in defined risk groups, hospital course, and survival, while also addressing the practical question many clinics care about most: whether the added processing cost produces enough real-world benefit to justify routine use. (pubmed.ncbi.nlm.nih.gov)